Ipsen SA is to expand its oncology portfolio with the acquisition of Epizyme Inc, a US developer of epigenetic medicines. Epizyme’s lead product, Tazverik (tazemetostat) has been approved for two cancer indications in the US – diseases that are not covered by Ipsen’s current portfolio.
